Regulus Therapeutics (RGLS) Reports In-Line Q3 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.40), in-line with the analyst estimate of ($0.40).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen